Tetrahydrobiopterin: Mediator of Endothelial Protection

Abstract

HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 24, No. 3Tetrahydrobiopterin: Mediator of Endothelial Protection Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBTetrahydrobiopterin: Mediator of Endothelial Protection Zvonimir S. Katusic and Livius V. d’Uscio Zvonimir S. KatusicZvonimir S. Katusic From the Department of Anesthesiology and Molecular Pharmacology, Mayo Clinic, Rochester, MN. Search for more papers by this author and Livius V. d’UscioLivius V. d’Uscio From the Department of Anesthesiology and Molecular Pharmacology, Mayo Clinic, Rochester, MN. Search for more papers by this author Originally published1 Mar 2004https://doi.org/10.1161/01.ATV.0000121569.76931.0bArteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:397–398During the past twenty years, the essential role of endothelial cells in preservation of vascular homeostasis has been well established.1,2 Protection of the vascular endothelium against harmful influences of circulating substances including excessive levels of lipids has been a major therapeutic approach in prevention of atherosclerosis. While endothelial dysfunction, defined as a loss of biologically active nitric oxide (NO) produced in the endothelium, has been recognized as a prime target for prevention and reversal of atherosclerotic process, identification of exact molecular mechanisms responsible for the loss of endothelial NO have been more difficult to determine. In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Alp et al3 report a series of elegant studies on genetically modified mice supporting the concept that NO synthase cofactor, tetrahydrobiopterin (Figure 1), is an important vascular protective molecule. The beneficial effect of tetrahydrobiopterin in apolipoprotein E (ApoE)-deficient mice appears to be mediated by preservation of endothelial nitric oxide synthase (eNOS) activity and production of nitric oxide in endothelial cells. Download figureDownload PowerPointThe major steps of tetrahydrobiopterin biosynthesis. GTP=guanosine 5′-triphosphate.See page 445In the early 1990s it was recognized that in the presence of suboptimal concentrations of tetrahydrobiopterin, activation of purified neuronal nitric oxide synthase (nNOS) causes “uncoupling of NOS” with subsequent increase in production of superoxide anions.4,5 These findings have been confirmed and extended to eNOS.6–8 This concept captured the imagination of vascular biologists for several reasons: (1) impaired biosynthesis of tetrahydrobiopterin can help to explain reduced production of NO and endothelial dysfunction in a variety of vascular diseases; (2) dysfunctional eNOS could become a major source of superoxide anions and contribute to oxidative stress in vascular disease; (3) tetrahydrobiopterin itself is a potent reducing molecule and could be attractive molecular target for oxidation; and (4) therapeutic interventions could be designed to increase endothelial concentration of tetrahydrobiopterin and “recouple eNOS”. Initial studies in isolated coronary arteries supported the notion that inhibition of tetrahydrobiopterin biosynthesis may alter endothelial function by increasing production of oxygen-derived free radicals.9 This was followed by measurements of BH4 levels in intact arteries demonstrating that single layer of endothelial cells account for more than 60% of total tetrahydrobiopterin present in the vascular wall.10,11 Consistent with these findings, it was demonstrated that GTP cyclohydrolase I, a rate-limiting enzyme in biosynthesis of BH4, is expressed and active in vascular endothelium.12–14 These early reports were followed by a number of studies on experimental animals and humans demonstrating the beneficial effect of tetrahydrobiopterin supplementation on endothelial dysfunction induced by hypercholesterolemia, diabetes, hypertension, and smoking (see recent review by Werner et al15). Oxidative stress is the common mechanism in pathogenesis of vascular disease, and accelerated oxidative degradation of tetrahydrobiopterin may provide an explanation for the consistent beneficial effect observed in a variety of animal models and patients with endothelial dysfunction. This hypothesis is strongly supported by the reported ability of an antioxidant, vitamin C, to stimulate eNOS enzymatic activity by increasing intracellular concentration of BH4.16–19 The effect of vitamin C appears to be mediated by chemical stabilization of tetrahydrobiopterin.The beneficial effect of tetrahydrobiopterin supplementation is based on the assumption that an insufficient amount of tetrahydrobiopterin is present in diseased arteries. However, measurements of tetrahydrobiopterin levels in aortas of atherosclerotic animals reported controversial results. Studies by Ozaki et al20 and Vasquez-Vivar et al21 reported reduced tetrahydrobiopterin in aortas of hypercholesterolemic mice and rabbits, respectively. In contrast, d’Uscio and colleagues19 reported increased tetrahydrobiopterin levels in aortas of ApoE-deficient mice. In the present study by Alp et al3 levels of tetrahydrobiopterin were not measured in control wild-type animals; however, presented findings are consistent with the reported increase of tetrahydrobiopterin in ApoE-deficient mice.19 The most likely explanation for the controversial findings is that studies by Ozaki et al20 and Vasquez-Vivar et al21 used atherosclerotic animals that had about 30 times higher circulating levels of cholesterol as compared with control animals. On the other hand, in studies by d’Uscio et al19 and Alp et al,3 total cholesterol levels were increased only about 3 times. Thus, it appears that hypercholesterolemia tends to increase tetrahydrobiopterin levels, whereas extremely high cholesterol levels can reduce availability of tetrahydrobiopterin. This finding is consistent with existing literature demonstrating stimulatory effect of proinflammatory cytokines on biosynthesis of tetrahydrobiopterin.13,14,22 These findings are also in line with reported increased plasma levels of neopterin, a byproduct of tetrahydrobiopterin biosynthesis, in patents with atherosclerosis and coronary syndrome.23,24 Interestingly, in the present study by Alp et al,3 additional increase in tetrahydrobiopterin due to over-expression of GTP cyclohydrolase I in endothelium of ApoE-deficient mice provided protection against atherosclerosis. This observation suggests that despite an apparent adaptive increase of tetrahydrobiopterin levels in aorta of ApoE-deficient mice, there appears to be a relative shortage of the NOS cofactor. Genetic supplementation of tetrahydrobiopterin preserved production of NO, reduced endothelial formation of superoxide anions, and protected vascular wall against atherosclerosis. Thus, tetrahydrobiopterin could be added to the list of endogenously produced antiatherosclerotic molecules, whereas endothelial GTP cyclohydrolase I is emerging as a potential new therapeutic target.Results of the study by Alp and colleagues3 are interpreted as additional evidence to support “eNOS uncoupling hypothesis” as an important mechanism of endothelial dysfunction. Studies by several different groups suggest that “eNOS uncoupling” could be prevented by tetrahydrobiopterin supplementation.9,11,25 However, as correctly pointed out by Alp et al,3 direct in vivo evidence of eNOS uncoupling is missing because of limitations of methodologies available to detect vascular superoxide anions.26 Furthermore, it remains puzzling how hypercholesterolemia-induced increase in tetrahydrobiopterin concentration in vascular wall may lead to uncoupling of eNOS in ApoE-deficient mice. Further studies of mechanisms involved in control of vascular GTP cyclohydrolase I expression and activity, as well as metabolism of tetrahydrobiopterin in endothelial cells in vivo, may ultimately provide explanation for the role of tetrahydrobiopterin in eNOS uncoupling. Irrespective of the exact mechanism underlying vascular protective effect of tetrahydrobiopterin, the study by Alp and colleagues3 provides strong evidence that tetrahydrobiopterin is an important endogenous antiatherosclerotic molecule.AcknowledgmentsThis work was supported in part by National Heart, Lung, and Blood Institute grants HL-53524, HL-58080, and HL-066958. The secretarial assistance of Janet Beckman is gratefully acknowledged.FootnotesCorrespondence to Zvonimir S. Katusic, Department of Anesthesiology and Molecular Pharmacology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Email [email protected] References 1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373–376.CrossrefMedlineGoogle Scholar2 Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens. 1999; 17: 1047–1058.CrossrefMedlineGoogle Scholar3 Alp NJ, McAteer M, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I over-expression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24: 445–450.LinkGoogle Scholar4 Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992; 281: 627–630.CrossrefMedlineGoogle Scholar5 Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem. 1992; 267: 24173–24176.CrossrefMedlineGoogle Scholar6 Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998; 95: 9220–9225.CrossrefMedlineGoogle Scholar7 Wever RMF, van Dam T, van Rijn HJM, de Groot PF, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun. 1997; 237: 340–344.CrossrefMedlineGoogle Scholar8 Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998; 273: 25804–25808.CrossrefMedlineGoogle Scholar9 Cosentino F, Patton S, d’Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, Malinski T, Luscher TF. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest. 1998; 101: 1530–1537.CrossrefMedlineGoogle Scholar10 Tsutsui M, Milstien S, Katusic ZS. Effect of tetrahydrobiopterin on endothelial function in canine middle cerebral arteries. Circ Res. 1996; 79: 336–342.CrossrefMedlineGoogle Scholar11 Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003; 111: 1201–1209.CrossrefMedlineGoogle Scholar12 Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K, Weiss G, Wachter H. Pteridine biosynthesis in human endothelial cells: impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem. 1993; 268: 1842–1846.CrossrefMedlineGoogle Scholar13 Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. J Clin Invest. 1994; 93: 2236–2243.CrossrefMedlineGoogle Scholar14 Katusic ZS, Stelter A, Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1998; 18: 27–34.CrossrefMedlineGoogle Scholar15 Werner ER, Gorren ACF, Heller R, Werner-Felmayer G, Mayer B. Tetrahydrobiopterin and nitric oxide: mechanistic and pharmacological aspects. Exp Biol Med. 2003; 228: 1291–1302.CrossrefMedlineGoogle Scholar16 Baker TA, Milstien S, Katusic ZS. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J Cardiovasc Pharmacol. 2001; 37: 333–338.CrossrefMedlineGoogle Scholar17 Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001; 276: 40–47.CrossrefMedlineGoogle Scholar18 Huang A, Vita JA, Venema RC, Keaney JF Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem. 2000; 275: 17399–17406.CrossrefMedlineGoogle Scholar19 d’Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003; 92: 88–95.LinkGoogle Scholar20 Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerated atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 2002; 110: 331–340.CrossrefMedlineGoogle Scholar21 Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol. 2002; 22: 1655–1661.LinkGoogle Scholar22 Gross SS, Jones CL, Hattori Y, Raman CS. Tetrahydrobiopterin: an essential cofactor of nitric oxide synthase with an elusive role. In: Nitric Oxide Biology and Pathobiology. San Diego, CA: Academic, 2000;167–187.Google Scholar23 Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 1991; 89: 203–208.CrossrefMedlineGoogle Scholar24 Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol. 1997; 30: 703–707.CrossrefMedlineGoogle Scholar25 Zheng J-S, Yang X-Q, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G, Kovesdi I, Chen AF. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation. 2003; 108: 1238–1245.LinkGoogle Scholar26 Munzel T, Afanas’ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol. 2002; 22: 1761–1768.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wu Y, Ding Y, Ramprasath T and Zou M (2021) Oxidative Stress, GTPCH1, and Endothelial Nitric Oxide Synthase Uncoupling in Hypertension, Antioxidants & Redox Signaling, 10.1089/ars.2020.8112, 34:9, (750-764), Online publication date: 20-Mar-2021. Jendzjowsky N, Just T, Jones K and DeLorey D (2014) Acute tetrahydrobiopterin supplementation attenuates sympathetic vasoconstrictor responsiveness in resting and contracting skeletal muscle of healthy rats, Physiological Reports, 10.14814/phy2.12164, 2:10, (e12164), Online publication date: 1-Oct-2014. Jones Buie J and Oates J (2014) Role of Interferon Alpha in Endothelial Dysfunction: Insights Into Endothelial Nitric Oxide Synthase–Related Mechanisms, The American Journal of the Medical Sciences, 10.1097/MAJ.0000000000000284, 348:2, (168-175), Online publication date: 1-Aug-2014. Erbas D (2013) Physiological Importance of Endothelium Endothelium, 10.1201/b14907-2, (1-71), Online publication date: 5-Jun-2013. Kolluru G, Bir S and Kevil C (2012) Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing, International Journal of Vascular Medicine, 10.1155/2012/918267, 2012, (1-30), . Capettini L, Cortes S, Silva J, Alvarez-Leite J and Lemos V (2011) Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis, British Journal of Pharmacology, 10.1111/j.1476-5381.2011.01500.x, 164:6, (1738-1748), Online publication date: 1-Nov-2011. Triggle C and Ding H (2010) A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS, Journal of the American Society of Hypertension, 10.1016/j.jash.2010.02.004, 4:3, (102-115), Online publication date: 1-May-2010. Ding H and Triggle C (2010) Endothelial dysfunction in diabetes: multiple targets for treatment, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-010-0807-3, 459:6, (977-994), Online publication date: 1-May-2010. Drouin A and Thorin E (2009) Flow-Induced Dilation Is Mediated by Akt-Dependent Activation of Endothelial Nitric Oxide Synthase-Derived Hydrogen Peroxide in Mouse Cerebral Arteries, Stroke, 40:5, (1827-1833), Online publication date: 1-May-2009. Steinberg M (2009) PATHOPHYSIOLOGY OF HEMOGLOBIN AND ITS DISORDERS Disorders of Hemoglobin, 10.1017/CBO9780511596582.012, (137-138) Kaul D (2009) Rheology and Vascular Pathobiology in Sickle Cell Disease and Thalassemia Disorders of Hemoglobin, 10.1017/CBO9780511596582.013, (139-157) Kaul D (2008) Sickle Cell Disease Microcirculation, 10.1016/B978-0-12-374530-9.00019-X, (769-793), . Kaul D (2008) Sickle Cell Disease Comprehensive Physiology, 10.1002/cphy.cp020417, (769-793), Online publication date: 1-Dec-2008. Rammos G, Peppes V and Zakopoulos N (2008) Transient Insulin Resistance in Normal Subjects: Acute Hyperglycemia Inhibits Endothelial-Dependent Vasodilatation in Normal Subjects, Metabolic Syndrome and Related Disorders, 10.1089/met.2007.0036, 6:3, (159-170), Online publication date: 1-Sep-2008. Fukai T (2007) Endothelial GTPCH in eNOS Uncoupling and Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 27:7, (1493-1495), Online publication date: 1-Jul-2007. Andresen J, Shafi N and Bryan R (2006) Endothelial influences on cerebrovascular tone, Journal of Applied Physiology, 10.1152/japplphysiol.00937.2005, 100:1, (318-327), Online publication date: 1-Jan-2006. d'Uscio L and Katusic Z (2006) Increased vascular biosynthesis of tetrahydrobiopterin in apolipoprotein E-deficient mice, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00366.2005, 290:6, (H2466-H2471), Online publication date: 1-Jun-2006. Pflueger A, Croatt A, Peterson T, Smith L, d'Uscio L, Katusic Z and Nath K (2005) The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II, American Journal of Physiology-Renal Physiology, 10.1152/ajprenal.00278.2004, 288:3, (F552-F558), Online publication date: 1-Mar-2005. Xu J, Wang S, Zhang M, Wang Q, Asfa S, Zou M and Xu A (2012) Tyrosine Nitration of PA700 Links Proteasome Activation to Endothelial Dysfunction in Mouse Models with Cardiovascular Risk Factors, PLoS ONE, 10.1371/journal.pone.0029649, 7:1, (e29649) March 2004Vol 24, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000121569.76931.0bPMID: 15003973 Originally publishedMarch 1, 2004 PDF download Advertisement